The beginning of embryogenesis is preceded by a sequence of events mediated by the release of intracellular calcium in the ooplasm, a multifaceted process known as oocyte activation. It is now well established that a sperm protein factor introduced into the oocyte at the time of gamete fusion is responsible for initiating the cascade of signaling events involved. Several sperm proteins have been hypothesized as the sperm oocyte-activating factor (SOAF) over the years, with phospholipase C zeta 1 (PLCZ1 or PLCzeta) emerging as the strongest candidate. A large body of consistent and reproducible evidence, from both biochemical and clinical settings, has accumulated in support of PLCzeta, and data clearly demonstrate that oocyte activation ability can be rescued in PLCzeta-deficient sperm by either PLCzeta cRNA or recombinant PLCzeta protein. However, a series of recent publications has challenged the dominance of PLCzeta and proposed an alternative candidate protein, WBP2 N-terminal like (WBP2NL or PAWP). These events have led to significant debate, fueled by the opposing views of two independent laboratories, each defending its own respective SOAF candidate. This raises important questions with regards to the relative importance of these two proteins in diagnostic and therapeutic medicine, and invites urgent research attention. Here, it is our intention to reflect upon this now very controversial area in order to engage the scientific and clinical communities in addressing the true importance of these two sperm proteins. intracellular calcium (Ca 2þ ), oocyte activation, PAWP, PLCf, perinuclear theca (PT), sperm oocyte-activating factor (SOAF)
INTRODUCTION
Fusion of a sperm with an oocyte initiates an intricate cascade of signaling pathways in the ooplasm, commencing with oocyte activation and eventually leading to early embryo development. Key events transpiring in the ooplasm during this period include cortical granule exocytosis, pronuclear formation, maternal mRNA recruitment, release of meiotic arrest, and the initiation of embryonic gene expression [1] [2] [3] [4] . A necessary component that triggers oocyte activation and these key events is the release of intracellular calcium (Ca 2þ ) stored in the endoplasmic reticulum (ER) [2] [3] [4] [5] . The exact manner in which Ca 2þ is released within the oocyte at fertilization has been debated for many years. Although consensus of opinion supports the involvement of a sperm oocyte-activating factor (SOAF) that is released into the oocyte upon gamete fusion, the identity of the precise sperm protein involved has been the source of much contention, with several candidates put forward for consideration [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . Here, we aim to provide an overview of the calcium-signaling pathway initiated within the oocyte upon gamete fusion, highlight the characteristics required of a SOAF, discuss past and present SOAF candidates, and critically consider recent controversial claims regarding two particular candidates.
CALCIUM SIGNALING UPON FERTILIZATION
The oocyte undergoes a major change upon fertilization as Ca 2þ stored in the ER is mobilized to the ooplasm in a carefully orchestrated temporal and spatial pattern, which ultimately initiates the cascade of molecular events that lead to oocyte activation [16, 17] . The frequency and amplitude of the evoked Ca 2þ release pattern, which can manifest as either a single transient in nonmammals or a series of periodic oscillations in mammalian species, are crucial in activating the oocyte successfully and ensuring that the early stages of embryogenesis proceed normally [4, 5, [18] [19] [20] .
Miyazaki et al. [17] provided distinct evidence that in mammalian oocytes, Ca 2þ is released via inositol-1,4,5-triphosphate receptors (IP 3 Rs) in the ER membrane following binding of inositol-1,4,5-triphosphate (IP 3 ). The findings of this study corresponded with earlier data suggesting that upon fertilization, a protein factor in the sperm was incorporated into the oocyte and subsequently led to the generation of IP 3 [16] . This line of evidence led to a concerted effort to identify the specific protein responsible, as clearly such a protein might hold significant diagnostic and/or therapeutic potential. The role played by this sperm protein is fundamental to the initiation of new life, and over time, the downstream cellular signaling system involved was elucidated in great detail. It is now well established that protein kinase C (PKC), Ca 2þ / calmodulin-dependent protein kinase II, and mitogen-activated protein kinase are all critical aspects of the downstream signaling cascade operating in an oocyte activated by Ca 2þ release [16, 17, 20, 21] . These signaling molecules, and the events they orchestrate, lead to the release of cortical granules and the formation of a pronucleus, and allow the oocyte to alleviate metaphase II (MII) arrest and begin embryogenesis (reviewed by Amdani et al. [22] ). Furthermore, we now know that a store-operated calcium entry (SOCE) mechanism exists within the oocyte and plays a vital role in calcium homeostasis. The SOCE mechanism involves a group of molecules (STIM1, ORAI1, and SERCA) and collectively permits the ER to refill with free Ca 2þ from the ooplasm in order to generate new Ca 2þ oscillations [23] . It follows that deficiency or abnormality in any of these signaling molecules or pathways may impart serious deleterious effects on the oocyte's ability to activate, and thus have adverse effects upon embryonic viability or fertility.
THE SOAF

Functional and Developmental Characteristics of a SOAF
General consensus suggests that in order for a protein factor to be considered as a SOAF it must possess appropriate functional and developmental characteristics. The theory arose that the definitive sperm factor should elicit Ca 2þ release from ooplasmic sources in a manner indistinguishable from that observed during mammalian fertilization [7, 11, 24] . This mechanism involves the increased production of IP 3 regulated by the phosphoinositide-signaling pathway [17] . The phospholipase C (PLC) family are cytosolic enzymatic proteins that catalyze the hydrolysis of phosphatidylinositol 4,5-biphosphate (PIP 2 ) to generate IP 3 and diacylglycerol (DAG). IP 3 causes the release of Ca 2þ via IP 3 Rs localized on the surface of the ER, whereas DAG and Ca 2þ activate the PKC pathway such that the Ca 2þ signals are transformed, or decoded, into cellular responses [5, [25] [26] [27] . There are currently 13 PLC isozymes that differ by structure and regulatory mechanisms, and although it has been suggested that some endogenous oocyte PLCs play a role in activation, there has been significant interest in identifying sperm PLCs [7, 14, 27, 28] , as these would represent strong candidates for a SOAF.
As with functional criteria, the precise location of a protein factor inside the sperm is a major factor to consider when assessing the credibility of potential SOAF candidates. The perinuclear theca (PT) of the sperm head is a region that contains cytoskeletal proteins crucial for maintaining sperm head architecture and coats the sperm nucleus [29] . Initially thought to be limited to cytoskeletal proteins, cytosolic proteins associated with fertilization are also present in the PT, a structure that spans three regions of the sperm head: a subacrosomal region, the equatorial segment, and the postacrosomal sheath-perinuclear theca (PAS-PT) [29, 30] . Fusion between the fertilizing sperm and oocyte begins in the equatorial segment and continues to the PAS-PT, the region that is first exposed to the ooplasm. Kimura et al. [31] investigated various aspects of the sperm's capability to activate oocytes by injecting the head or tail from mouse sperm into mouse oocytes and found that this practice either did or did not induce activation, respectively. Further tests aimed to identify the specific region of the sperm head accountable for such activity. It was deduced that sperm heads treated with Triton X-100 retained the ability to induce oocyte activation whereas those treated with trypsin or SDS failed to elicit activity [31] . Microscopic evidence revealed that treatment with Triton removed all membranes except the PT around the nucleus but treatments with trypsin or SDS vastly altered or removed the PT. These findings were later supported by Perry et al. [32, 33] . It followed, therefore, that the SOAF must reside in the PT [29] . These early experiments and findings played a key role in facilitating and directing targeted research into identifying specific SOAF candidates. Historically, however, the primary concern focused upon the exact mechanism by which the sperm first introduces the SOAF upon gamete fusion.
Historical Perspectives: Theories of the SOAF's Mechanism of Action ''Sperm factor'' and ''receptor-based'' mechanisms were the two dominant theories and the focus of much debate for over a century. Although both seemed entirely feasible, the ''sperm factor'' mechanism, in which a soluble sperm factor was thought to be released into the oocyte in order to trigger oocyte activation, was rapidly accepted in favor of the opposing theory [16, 34, 35] . The combination of advanced intracellular calcium imaging technology, the failure to identify an appropriate ''receptor-based'' mechanism, and the clinical use of intracytoplasmic sperm injection (ICSI)-a technique that is successful but bypasses any sperm/oocyte membrane binding mechanism-led to the almost complete dismissal of a sperm-ligand binding to an oocyte receptor in order for activation to commence [7, 8, 16, 36, 37] .
Given its fundamental importance to successful fertilization, the clinical relevance of the SOAF cannot be denied. Oocyte activation deficiency (OAD) and total fertilization failure (TFF) are known causes of infertility, and are common in cases of recurrent ICSI failure. Reported abnormalities in SOAF, or the associated molecular machinery within the oocyte, are thus likely to be the predominant underlying causes of OAD and TFF [11, 22, 26, [38] [39] [40] . It follows that a certain subset of idiopathic cases of infertility may also be affected. Despite the advances in modern laboratory technology, and our ability to image Ca 2þ in living cells, our diagnostic and therapeutic options for cases of OAD or TFF in the clinic remain highly restricted unless the specific proteins involved are identified and can be assayed accurately. Clearly such proteins, whether sperm-or oocyte-borne, represent valuable pharmaceutical targets.
Identification of SOAF Candidates
Two proteins, glucosamine-6-phosphate isomerase (GPI) and citrate synthase, were proposed as initial SOAF candidates but were soon cast aside. GPI, a homologue of hamster oscillin, was the first sperm protein proposed as the putative soluble sperm factor as it was associated with Ca 2þ oscillation-inducing activity in mammalian eggs [35, 41] . This proposition was supported clinically by the fact that the localization of oscillin in the equatorial segment of human sperm appeared to have a positive impact upon oocyte activation and fertilization rates [42] . However, Parrington et al. [35, 41] failed to demonstrate the functional activity of oscillin, and ensuing experiments from Wolosker et al. [43] showed that hamster oscillin failed to induce Ca 2þ oscillations following injection into mouse oocytes. Similarly, Wolny et al. [44] reported that the recombinant form of human GPI failed to generate Ca 2þ oscillations when injected into mouse oocytes. In addition, Wolny et al. [44] used antibodies and immunodepletion methods to show that GPI was unable to block Ca 2þ oscillations. In contrast, injections of human sperm cytosolic factor consistently induced Ca 2þ oscillations in mouse oocytes, leading to the deduction that a protein other than GPI was responsible for Ca 2þ oscillationinducing activity [44, 45] . Next, the potential of citrate synthase as a SOAF emerged when a purified 45-kDa protein, AMDANI ET AL.
homologous to Xenopus citrate synthase, was injected into the unfertilized oocytes of the newt, Cynops pyrrhogaster, and induced oocyte activation [46] . Although this protein initially appeared to be a promising candidate, at least in the newt, there have been no subsequent reports describing the possible involvement with mammalian fertilization.
Attention soon turned to PLC zeta 1 (PLCZ1; more commonly referred to as PLCf in the literature), which rapidly gained significant support among the scientific and clinical community as the predominant SOAF candidate. Mounting biochemical and clinical evidence still points to PLCf as being the dominant protein responsible for activating oocytes at fertilization [7, 8] . However, over recent years, a new candidate has emerged, WBP2 N-terminal like (WBP2NL) protein, commonly referred to as PAWP. PAWP localizes in an appropriate region of the sperm head and causes Ca 2þ oscillations when injected into oocytes, and protein levels have been correlated with fertilization outcome [9] . However, some of the emergent data relating to PAWP have been queried openly in the scientific literature, leading to significant confusion, particularly in the clinical arena. It is thus the intention of this review to focus particularly upon PLCf and PAWP, and the mounting debate surrounding the relative importance of these two proteins (Table 1) .
PHOSPHOLIPASE C ZETA
Although initial belief was that the SOAF was most likely to be a sperm PLC, largely because of the intimate association between PLC molecules and the generation of IP 3 , it was evident that none of the known PLC isoforms at the time could induce Ca 2þ release in an oocyte in a manner similar to that observed during normal fertilization. However, experiments using a mouse testis expressed sequence tag database finally resulted in the identification of a novel PLC isoform, referred to as PLCf [7] . PLCf is the smallest known PLC, and since derivation has been studied on a global scale given its potential clinical worth. Initial evidence of its dominant role as the Total levels of PAWP in bull and human spermatozoa are correlated with sperm quality and fertilization rates. 
SPERM FACTORS AND OOCYTE ACTIVATION
SOAF began when cRNA synthesized against PLCf was microinjected into mouse MII-arrested oocytes. Resultant data revealed a normal Ca 2þ release profile and successful development to the blastocyst stage [7] . Further proof that PLCf was the only sperm component accountable for Ca 2þ release was the failure to generate Ca 2þ activity when PLCf was depleted from sperm extracts. Moreover, fractionation experiments concluded that following ICSI, PLCf was the only sperm protein responsible for the Ca 2þ oscillations observed [7] . Knott et al. [66] provided further supporting evidence by reporting that PLCf-deficient sperm, created via the use of RNA interference technology in transgenic mice, resulted in Ca 2þ oscillations that ended prematurely upon injection into mouse oocytes. The structure of PLCf is significant in executing its role in oocyte activation as each domain (X and Y catalytic domains, EF hands, and a C2 domain) plays an integral part in exerting function [5, 25, 27, 53, 57] . Removal or mutation of these domains results in failure to evoke Ca 2þ oscillations, or leads to abnormal profiles of Ca 2þ release [25, 53] . However, it would be presumptuous to disregard the involvement of the oocyte, as PLCf is heavily implied to be active only when introduced into the ooplasm [67, 68] . The oocyte, therefore, has acquired a vital role in triggering the enzymatic activity of PLCf upon fertilization [11, 53] . Indeed, the hypothesized interaction of PLCf with receptor-bound vesicles within the oocyte containing PIP 2 for hydrolysis [59] suggests critical communication between PLCf and oocyte components (Fig.  1 ). An important future goal for researchers is therefore to identify the specific receptors within the oocyte that interact with PLCf in order to acquire functional ability. Such receptors may clearly represent useful diagnostic markers or therapeutic targets, as not all cases of OAD or TFF may be attributable to sperm deficiency.
Clinical Links Between PLCf and Male-Factor Infertility
In addition to the compelling body of functional and biochemical evidence that has been accrued thus far, a number of clinical studies have also helped to consolidate the role of PLCf as the dominant SOAF candidate. Identifying the spatial expression of PLCf in human sperm was first necessary in order to interpret its involvement in human infertility. PLCf expression was evident in three separate localization patterns within the human sperm head: the acrosomal region, the equatorial segment, and the postacrosomal region, possibly suggesting that different populations of PLCf might play differential functional roles that are not limited to oocyte activation [11, 55, 69, 70] . The first clinical association between PLCf and male infertility showed that PLCf-deficient sperm from patients who had experienced unsuccessful attempts at ICSI failed to evoke Ca 2þ oscillations when microinjected into mouse oocytes [61] . However, the ability to induce Ca 2þ oscillations in oocytes was rescued when such 3 , which then binds to IP 3 Rs to cause the pulsatile release of Ca 2þ from the endoplasmic reticulum. PAWP is hypothesized to bind to oocyte-borne YAP proteins, and then via the resultant Src Homology 3 binding motif (SH3-BM) to the SH3 domain of PLCc in order to activate the phosphoinositidesignaling pathway in a similar mechanism to PLCf. Structural features of PLCf and PLCc are modified from Saunders et al. [7] . PAWP (Q6ICG8) and YAP (P46937) structural features were obtained by the description provided from Universal Protein Resource [80] .
AMDANI ET AL.
sperm were injected coincident with PLCf mRNA, thus providing robust evidence that the infertile phenotype was correlated to PLCf deficiency [61] .
Genetic links between abnormal PLCf and infertility have provided further support for the fundamental role of PLCf both in clinical settings [62, 63] and potentially in the breeding of agricultural livestock [64] . The first genetic link involved the identification of two mutant PLCf isoforms in an infertile nonglobozoospermic male [62, 63] . Genetic analysis of the genomic DNA encoding PLCf in this patient revealed the substitution of histidine for proline at position 398 (H398P) and of histidine for leucine at position 233 (H233L) within the Y and X catalytic domains, respectively. These mutations disrupted secondary structure of the PLCf protein, resulting in failure to initiate Ca 2þ release, or led to the production of an abnormal pattern of Ca 2þ oscillations when cRNA derived from PLCf H398P and PLCf H233L was injected into mouse eggs, respectively [62, 63] . More recently, Pan et al. [64] reported genetic variants in the PLCf promoter of Chinese Holstein bulls, but failed to provide robust evidence of a direct effect of these variants upon specific PLCf parameters.
The evident relationship between PLCf deficiency and human infertility understandably prompted researchers to investigate the applications of this fundamental protein in the clinic. The development of specific techniques such as immunofluorescence and Western blotting now allows us to investigate relative levels and localization patterns in human semen samples, and thus create a bioassay for oocyte activation ability. More importantly, a pure and active form of recombinant human PLCf (hrPLCf) will clearly help restore oocyte activation ability in cases of OAD or TFF, thus representing a valuable pharmaceutical agent.
PLCf As a Novel Therapeutic Option for OAD
ICSI is widely considered to be a landmark treatment option for severe male infertile conditions and remains a robust and effective technique. However, 1%-5% of ICSI cycles are still known to fail and OAD is widely considered to be the root cause for such failures. At present, the only way to treat such cases is via the use of artificial oocyte activators (AOAs), and although some clinics deploy such techniques, there is widespread concern over the potentially deleterious effects these chemical agents may have upon the resultant embryo [71] . Production of an active and purified hrPLCf protein would be a much more desirable treatment option than AOAs as it represents a far safer and more endogenous option [11, 72] . However, the purification process remains the biggest obstacle to this quest, and although several attempts have shown clear promise, particularly in the form of mammalian lysates or purified proteins from bacterial cell lines, there are still numerous concerns over existing proteins with respect to their potential clinical application [60, 72, 73] . The most promising study recently generated hrPLCf from a bacterial cell line using a Nus-A-tagged protein that when microinjected into mouse oocytes exhibited Ca 2þ oscillations identical to normal fertilization [12] . The same hrPLCf also rescued the activation ability of mouse oocytes previously administered with mutant PLCf H398P and PLCf H233L cRNA [12] . Although concerns remain with respect to the relative size of the Nus-A tag and its absolute requirement for activity and stability, these findings do provide convincing evidence that PLCf is a particularly strong SOAF candidate. However, over recent years, a series of reports have emerged that question the dominance of PLCf, and instead have put forward an alternative candidate protein.
POSTACROSOMAL WW-DOMAIN BINDING PROTEIN
Almost half a decade since its discovery, PLCf appeared dominant in its role as the putative SOAF responsible for oocyte activation. A host of studies from many independent laboratories have validated its role as a SOAF in a reproducible and consistent manner, from both molecular and clinical perspectives [7, 8, 12, 52, 56, 61-63, 66, 72] . However, the role of PLCf is currently challenged by the emergence of an alternative SOAF candidate, postacrosomal WW-binding domain protein, or PAWP. This new candidate is a spermspecific protein presumed to alleviate meiotic arrest and initiate pronuclear formation following fertilization, thus prompting a presumptive role in activating the oocyte [9] . The structure of PAWP is distinct in that the N terminal exhibits sequence homology to WW domain-binding protein 2, a proline-rich Cterminal consisting of a PPXY consensus binding site for group-1 WW domain-containing proteins (PY motifs) and an unknown repeating motif (YGXPPXG) [9, 58] . The precise signaling mechanism of PAWP within the oocyte remains speculative, but recent data suggest that PAWP binds to group-1 WW domain proteins such as yes-associated protein (YAP), expressed in the oocyte, and that it interacts with the SH3 domain of oocyte phospholipase C gamma (PLCc) in order to modulate the phosphoinositide-signaling pathway (Fig. 1) [9, 14] . This proposal remains, however, purely theoretical, and it is therefore crucial to elucidate the precise signaling mechanism involved before the relative role of PAWP in oocyte activation can be considered in a robust manner. However, current data do appear to show that PAWP, at least, does exhibit acceptable characteristics of a SOAF, and cannot, therefore, be ignored.
PAWP was first reported in 2007 [9] ; immunocytochemical staining of bull testicular tissue with an antibody raised against recombinant PAWP (recPAWP) revealed the expression of PAWP in the elongated spermatid population. PAWP was first detected in stage 9 of the bull spermatogenic cycle, reaching maximal levels during stages 11 and 12. The localization of PAWP was restricted to the PAS-PT of mature sperm from different species and demonstrated by immunofluorescent or immunogold labeling methods [9] . These crucial findings were also confirmed by the work of Wu et al. [49] and Ito et al. [50] . In addition to the developmental features of PAWP, Wu et al. [9] analyzed its functional characteristics by microinjecting recPAWP and alkaline PT extract into porcine, bovine, and Xenopus oocytes. These microinjections consistently formed a pronucleus and alleviated oocytes from MII arrest [9] . This encouraging finding provided a prerequisite step with which to expand investigations into the involvement of PAWP with calcium signaling and oocyte activation. Only recently, Aarabi et al. [14] demonstrated that PAWP cRNA or recPAWP was able to induce calcium oscillations and oocyte activation when microinjected into human and mouse oocytes. Furthermore, the release of Ca 2þ was prevented following the microinjection of a human sperm coincident with a competitive inhibitor, PAWP-derived PPGY peptide, thus providing credible data that PAWP is necessary for oocyte activation [14] . Recent work has also shown an association between the expression of human and bull PAWP and sperm quality and fertility capabilities following ICSI and artificial insemination [51, 65] . Collectively, therefore, PAWP appears to have fulfilled the relevant conditions to classify as a strong candidate for SOAF. Interestingly, however, while stressing the importance of PAWP for oocyte activation, Aarabi et al. [69] also questioned the role of PLCf, and this has led to much debate and confusion.
SPERM FACTORS AND OOCYTE ACTIVATION
CONFLICTS BETWEEN OLD AND NEW SOAF CANDI-DATES
Aarabi et al. [69] claimed that much controversy lies within the known expression profile of PLCf during spermatogenesis as there is insufficient evidence to fully describe how PLCf protein is translated at present. One particular study reported that PLCf mRNA in the boar and mouse was first expressed in round spermatids and possibly translated during the elongated spermatid stage [47] . To date, there has been no follow-up study to confirm this hypothesis. Another pressing issue is related to the localization profile of PLCf, as findings from Aarabi et al. [69] showed that human PLCf was located over the sperm membrane or acrosomal region, but not as a component of the PAS-PT. This became evident from a fractionation experiment using nonionic detergent that showed that PLCf was absent from the pellet-the fraction in which the PAS-PT was retained and that therefore should have contained the SOAF [69] . Conversely, in the mouse, PLCf was indeed present in the pellet, but was localized to the isolated sperm tails instead of sperm heads [48] . Further results from immunoperoxidase staining and immunogold labeling of human testicular germ cells detected PLCf at the round spermatid stage of spermatogenesis but then showed that PLCf progressively diminished throughout the remainder of spermiogenesis. Furthermore, in vitro fertilization (IVF) experiments using boar sperm indicated that PLCf could no longer be detected following fertilization, suggesting that PLCf was released along with the acrosomal cap [69] . The same study [69] also detected PLCf localization over the surface of the sperm head, specifically in the postacrosomal region of mouse sperm and both the postacrosomal and acrosomal regions in human sperm. Further investigation deduced that PLCf was not strictly a testis-specific protein, but was also expressed in the epididymis. This correlated to its localization over the entire surface of the sperm head, and explained the disappearance of PLCf following boar sperm IVF, in which PLCf was lost along with the acrosomal and surface proteins. Collectively, the findings from Aarabi et al. [69] led to the conclusion that PLCf cannot be the primary SOAF candidate, as it originates from the developing acrosome instead of the forming PAS-PT and is therefore merely an acrosomal component lost during fertilization. These lines of evidence reported by Aarabi et al. [69] appear to be rational and it is evident that the credence of PLCf as a SOAF is now under scrutiny, but there are important factors that need to be addressed in order to confirm or refute the claims of these authors.
The unusual PLCf localization patterns reported by Aarabi et al. [69] contrast starkly with research data arising from other research groups spanning 6 years, which have consistently shown PLCf to be a cytosolic protein localized to three defined regions within the sperm head [11, 54, 55, 74, 75] . A recent study has now reported the subcellular localization of PLCf for the first time, and these new data create further contention. According to Escoffier et al. [56] , PLCf is indeed localized to the PT of the equatorial and postacrosomal regions of human sperm. Furthermore, PLCf was predominantly located in the equatorial region of the PT, where the sperm fuses with the oocyte. Moreover, Zanetti and Mayorga [76] showed that the equatorial region remains unchanged following the acrosome reaction, thus contradicting the findings of Aarabi et al. [69] . It is also worth noting that an earlier study involving mouse and porcine sperm confirmed that PLCf originated in the perinuclear matrix, an oocyte-penetrating region [52] . The latest finding from Escoffier et al. [56] may have reaffirmed PLCf's position as a dominant SOAF candidate, as it already exhibits the appropriate functional characteristic of Ca 2þ oscillation-inducing activity in mammalian eggs. However, an important next step might be to block PLCf activity via the use of PLCf-specific antibodies and/or competitive peptides during ICSI [14, 69] . Confirming the intrinsic involvement of PLCf during the process of ICSI would provide key supportive data for PLCf as the SOAF, with specific clinical implications. However, PAWP has successfully been shown to exhibit the appropriate functional and developmental characteristics of a SOAF, and therefore also deserves specific study during the ICSI process.
The most contentious issue, however, is that significant conflict has emerged with regards to the Ca 2þ release ability of PAWP, as addressed by Nomikos et al. [77] . Aarabi et al. [14] reported that the microinjection of recPAWP into mouse and human oocytes elicited Ca 2þ oscillations similar to those seen following ICSI. This represented a major line of evidence to support a potential role for PAWP in oocyte activation. However, Nomikos et al. [77] replicated these experiments and injected recombinant versions of PLCf and PAWP into mouse oocytes to monitor the respective Ca 2þ release profile elicited. Results showed that recombinant PLCf initiated Ca 2þ release in a manner similar to that reported previously in 100% of oocytes injected, in line with that seen normally at fertilization. However, in their hands, recombinant PAWP protein, or PAWP cRNA, did not cause Ca 2þ release, even following modifications of rPAWP concentration or the use of various tagged and untagged forms of PAWP cRNA. Nomikos et al. [77] used these data to imply that PAWP is not a convincing SOAF candidate. However, given this conflict, and the clinical significance of the proteins concerned, it is important not to jump to any premature conclusions. For example, it is possible that methodological differences between the two groups [14, 77] , particularly in relation to recombinant protein expression, may have contributed to the observed differences in functional ability. Differences in host systems, reagents, protein purification tags, or even incubation times could all play a role in the distinct observations of [14] and [77] , and clearly highlight the future need for a unified and consistent approach. Collectively, these two functional studies [14, 77] have created significant confusion in the field. Given the growing debate surrounding the relative importance of PLCf and PAWP in the initiation of oocyte activation [13-15, 77, 78] , it is now imperative for the two opposing groups involved to consolidate and verify their evidence, and for other research teams to provide independent data and analysis.
CONCLUSION
Regardless of the relative dominance of PLCf in the scientific and clinical literature, it would be very unwise to dismiss PAWP outright at this moment in time without appropriate independent authentication. What has been established is that 1) PAWP is a sperm-specific protein localized to a region of the sperm that is involved in oocyte activation; 2) PAWP has the ability to induce Ca 2þ oscillations in oocytes, and this activity is blocked by relevant antibodies and/or competitive peptides; and 3) there appears to be a positive correlation between PAWP content in human sperm and fertilization rates for patients undergoing assisted reproductive technology. However, it is also clear that controversy remains in the marked conflict between the respective datasets reported by Aarabi et al. [14] and Nomikos et al. [77] , especially with respect to the functional ability of PAWP to cause Ca 2þ release in oocytes. Further independent verification and validation of this particular biological property is now an absolute necessity.
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Creating gene knockout mouse models would certainly help to address the specific role of these two sperm proteins. The lack of a fully published knockout PLCf mouse still remains a fundamental concern. Although initial attempts to create such a mouse were reported at a scientific conference [79] , data were never published in a peer-reviewed academic journal, perhaps because such mice exhibited aberrant patterns of spermatogenesis. Similarly, a PAWP knockout model has yet to be reported. Derivation of such powerful transgenic models will undoubtedly help us to unravel the relative importance of PAWP and PLCf. It is also vital that future work aim to elucidate potential correlates between the expression and function of PAWP and specific cases of OAD and TFF in the clinic. Studies of this type are imperative in developing new diagnostic assays and therapeutic agents for those couples experiencing OAD and TFF, a growing subset of patients who have no other remedial alternative at present but to use AOAs. The need for more endogenous treatment options is becoming highly apparent among fertility clinics, and patients experiencing OAD and TFF are increasingly turning to the scientific literature for diagnostic clues and potential answers to their problems. Patients already have access to a vast library of information relating to how PLCf relates to OAD, TFF, and recurrent ICSI failure. It is now very important that we address the confusion and conflict surrounding PAWP and systematically characterize its relative importance for the infertile patient.
